Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma

C. Owen MD, N.L. Berinstein MD, A. Christofides MSc RD, and L.H. Sehn MD

ABSTRACT

Mantle cell lymphoma (MCL) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Patients typically require multiple lines of therapy, and those with relapsed or refractory (R/R) disease have a very poor prognosis. The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has proven to be an effective agent for patients with R/R MCL. Although usually well tolerated, ibrutinib can be associated with unique toxicities, requiring discontinuation in some patients. Effective and well-tolerated alternatives to ibrutinib for patients with R/R MCL are therefore needed. Novel BTK inhibitors such as acalabrutinib, zanubrutinib, and tirabrutinib are designed to improve on the safety and efficacy of first-generation BTK inhibitors such as ibrutinib. Data from single-arm clinical trials suggest that, compared with ibrutinib, second-generation BTK inhibitors have comparable efficacy and might have a more favourable toxicity profile. Those newer BTK inhibitors might therefore provide a viable treatment option for patients with R/R MCL.

Key Words  Bruton tyrosine kinase inhibitors, mantle cell lymphoma, acalabrutinib

INTRODUCTION

Mantle cell lymphoma (MCL), a rare subtype of non-Hodgkin lymphoma (NHL) with an aggressive clinical course and poor prognosis, is considered incurable in almost all affected patients. In Canada, approximately 500 new cases of MCL are diagnosed each year, comprising 4%–10% of all NHLs. Mantle cell lymphoma occurs more frequently in men than in women, and it is usually diagnosed in older adults at a median age of 68 years. Patients with MCL typically present with advanced-stage disease, including lymphadenopathy, bone marrow involvement, splenomegaly, circulating tumour cells, and bowel involvement; they frequently require immediate treatment.

Median overall survival (OS) duration from initial diagnosis of MCL has historically been poor, ranging from 29 to 51 months depending on clinical risk, as assessed by the Mantle Cell Lymphoma International Prognostic Index. However, survival appears to have improved with the advent of newer therapies.

Standard treatment for advanced MCL is based on patient age and comorbidities. Younger, fit patients are treated with induction immunotherapy, followed by autologous stem-cell transplantation and rituximab maintenance. Excellent OS and progression-free survival (PFS) have been obtained with aggressive regimens that incorporate cytarabine into an anthracycline-containing induction regimen followed by autologous stem-cell transplantation. Older patients who are not appropriate for stem-cell transplantation are typically treated with chemoimmunotherapy and rituximab maintenance, with bendamustine–rituximab commonly being used as induction.

Although initial treatment strategies achieve high response rates, most patients will eventually relapse and require further therapy, which generally results in shorter periods of remission with each subsequent therapy. Therapeutic options in the relapsed setting include consideration of alternative chemoimmunotherapy and a growing list of novel therapies that have demonstrated efficacy in patients with relapsed or refractory (R/R) MCL. The latter therapies include the proteasome inhibitor bortezomib, the mechanistic target of rapamycin inhibitor temsirolimus, the immunomodulatory drug lenalidomide, and...
the Bruton tyrosine kinase (Btk) inhibitors ibrutinib and acalabrutinib. The B-cell lymphoma 2 inhibitor venetoclax is also showing promise, but is not yet approved for MCL. Although those therapies have not been compared in randomized studies, data from phase II trials suggest that Btk inhibitors are among the most effective agents in the r/r MCL setting.12–14

The Btk non-receptor protein kinase is an important mediator in the B-cell receptor signalling pathway, instrumental in the proliferation and survival of MCL cells. The first-generation Btk inhibitor ibrutinib has been associated with response rates of 54%–72% in patients with r/r MCL, with complete response (CR) rates in the 19%–23% range.1,12,13. Although generally well tolerated, ibrutinib does have a unique toxicity profile. Some patients inevitably discontinue therapy because of associated toxicities such as cytopenias, infection, pneumonitis, diarrhea, bleeding, and atrial fibrillation.15 In addition, a large proportion of treated patients do not achieve a CR with ibrutinib, and other effective and well-tolerated options are therefore needed.

A number of second-generation Btk inhibitors are in various stages of development; they are designed to improve on the safety and efficacy of first-generation Btk inhibitors such as ibrutinib. The purpose of the present paper is to provide an overview of Btk inhibitors for the treatment of r/r MCL, a discussion of how those agents might be used within the Canadian treatment landscape, and possible future applications in other hematologic malignancies.

CURRENT TREATMENT OPTIONS IN R/R MCL

In the United States, the U.S. Food and Drug Administration (FDA) has approved a total of 4 agents for the treatment of r/r MCL, including bortezomib (approved in 2006),16 lenalidomide (approved in 2013), ibrutinib (approved in 2013), and acalabrutinib (approved in 2017).17 In addition, temsirolimus was approved in Europe in 2009. However, in Canada, only 2 agents are approved in this setting: bortezomib18 and ibrutinib19. Furthermore, public funding for ibrutinib in r/r MCL is available in only some provinces in Canada.

Despite recent approval of novel therapies, management of r/r MCL remains challenging. Overall response rates (ORRs) range from 22% to 81%, depending on the type of treatment, with median progression-free survival (PFS) ranging from 3.9 months to 14.6 months.12,13,21–29 Median overall survival (OS) remains short, in the range of 1–2 years (Table 1).

Although no current standard of care in the r/r setting has been established, and no randomized trials comparing therapies have been published, phase I and II trials suggest that ibrutinib might have the most promising single-agent activity of the agents currently approved in Canada, with ORRs ranging from 54% to 72%, and median PFS ranging from 13.6 months to 14.6 months.12,13. Those outcomes compare favourably with the reported median PFS for bortezomib, lenalidomide, and temsirolimus (9.2 months, 3.9–8.7 months, and 4.8–6.2 months respectively, Table 1). More recently, the published phase II ACE-LY-004 study examining the efficacy of a novel Btk inhibitor, acalabrutinib, in r/r MCL also demonstrated promising efficacy with an ORR of 81%14. In addition, CR rates with acalabrutinib were notable at 40%. Those results appear favourable compared with results reported for ibrutinib, but the relevant studies were not comparable in terms of number and types of prior therapies, with patients in the acalabrutinib trial being less heavily pretreated (median: 2 vs. 3 prior therapies) and with differences in the types of prior therapies given (7% vs. 24% receiving lenalidomide, for example). Results of the ACE-LY-004 study, in October 2017, to the accelerated approval of acalabrutinib by the FDA for the treatment of patients with MCL whose cancer has progressed after receiving at least 1 prior therapy.14,30 However, acalabrutinib is not yet approved in Canada for patients with r/r MCL.

| Study | Patients | ORR (%) | CR (%) | Median PFS (months) |
|-------|----------|---------|--------|---------------------|
| Acalabrutinib | Wang et al., 2018 | 124 | 81 | 40 | NR |
| Ibrutinib | Advani et al., 2013 | 9 (of 56 total) | 54 | — | 13.6 |
| | Wang et al., 2015 | 111 | 67 | 23 | 13.0 |
| | Dreyling et al., 2016 | 280 | 72 | 19 | 14.6 |
| Bortezomib | Fisher et al., 2006 | 155 | 33 | 8 | 9.2 |
| | Strauss et al., 2006 | 24 (of 51 total) | 29 | 4 | — |
| Lenalidomide | Wiernik et al., 2008 | 15 (of 49 total) | 53 | 7 | 5.6 |
| | Zinzani et al., 2013 | 57 | 35 | 12 | 8.8 |
| | Eve et al., 2013 | 26 | 31 | 7 | 3.9 |
| | Guy et al., 2013 | 134 | 26 | 8 | 4.0 |
| | Trneny et al., 2015 | 254 | 40 | — | 8.7 |
| Temsirolimus | Hess et al., 2009 | 162 | 22 | — | 4.8 |
| | Dreyling et al., 2016 | 280 | 40 | 1 | 6.2 |

ORR = overall response rate; CR = complete response; PFS = progression-free survival.

BTK INHIBITORS IN R/R MCL

The Btk non-receptor protein kinase is a member of the Tec protein tyrosine kinase family that is expressed in B-cells, myeloid cells, mast cells, and platelets. A key component of the B-cell antigen receptor signalling cascade, Btk is involved in all aspects of B-cell development, including proliferation, maturation, differentiation, apoptosis, and cell migration. As such, Btk plays a critical role in the progression of B-cell lymphoproliferative disorders and is therefore an attractive target for treating B-cell malignancies.
First-Generation BTK Inhibitors

**Ibrutinib**

Ibrutinib is a once-daily oral BTK inhibitor that binds co-valently to a cysteine residue (Cys481) in the active site of the BTK-atp-binding domain of BTK, inhibiting B-cell receptor signalling and thereby reducing cell growth, proliferation, survival, adhesion, and migration. In addition to its use in r/r MCL, ibrutinib is also approved by Health Canada for the treatment of other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, marginal zone lymphoma, and chronic graft-versus-host disease.

Results of a multicentre single-arm phase II study (PCYC-1104) led, in November 2013, to the approval of ibrutinib by the FDA for the treatment of patients with MCL who have received 1 prior therapy. Patients included in the study had a median age of 68 years, and 86% had intermediate-risk or high-risk MCL according to clinical prognostic factors, with a median of 3 prior therapies. At an initial median follow-up of 15.3 months, the ORR was 68%, and the CR rate was 21% according to the International Working Group 2007 response criteria. The estimated median PFS was 13.9 months, with a median duration of response (DOR) of 17.5 months. At a later median follow-up of 26.7 months, the ORR was 67%, and the CR rate was 23%. The median PFS was 13 months, with a median DOR of 17.5 months (Table I, supplementary Appendix 1).

The most common adverse events (AEs), experienced by more than 30% of the patients, included diarrhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%) (Table II, supplementary Appendix 1). Common all-grade hematologic AEs were thrombocytopenia (22%), neutropenia (19%), and anemia (18%). The most frequent grade 3 or greater infections included pneumonia (8%), urinary tract infections (4%), and cellulitis (3%). All-grade bleeding events were reported in 50% of the patients. Grade 3 or greater bleeding events in more than 2% of the patients were hematuria (2%) and subdural hematoma (2%). Atrial fibrillation was reported in 11% of the patients, with grade 3 events occurring in 6% of the patients. No grade 4 or 5 events were observed. Discontinuations as a result of treatment toxicity occurred in 11% of the patients.

A number of subsequent studies examining ibrutinib in r/r MCL were conducted, and they supported the results from PCYC-1104 (supplementary Appendix 1). Although results from clinical trials showed that ibrutinib was well tolerated by most patients, further experience with ibrutinib, as demonstrated by real-world data, showed higher discontinuation rates than had been reported in clinical trials. A study by Mato et al. compared the type and frequency of toxicities seen with ibrutinib in clinical trials and in a real-world setting. Although that study included patients with CLL and not MCL, it had interesting findings. At a median follow-up of 14.5 months, the ibrutinib discontinuation rate was estimated to be 42% (median time to ibrutinib discontinuation: 7 months). Moreover, discontinuations that occurred as a result of toxicity appeared higher in the real-world setting (52.5%) than in clinical trials (38.7%). Toxicities related to ibrutinib were the most common reason for discontinuation in all patients. The most common ibrutinib-related toxicities leading to discontinuation included atrial fibrillation (12.3%), infection (10.7%), pneumonitis (9.9%), bleeding (9%), and diarrhea (6.6%).

Two studies have examined ibrutinib combined with other molecules for the treatment of r/r MCL (supplementary Appendix 1). Those studies demonstrated ORRs of 71% and 88% when ibrutinib was combined with venetoclax and rituximab respectively. However, as expected, both studies reported rates of all-grade toxicities that were higher than those seen when ibrutinib was used alone.

Second-Generation BTK Inhibitors

Although the first-generation BTK inhibitor ibrutinib has proven to be highly effective, it also has a number of off-target effects by inhibiting other tyrosine kinases such as epidermal growth factor receptor, interleukin 2–inducible T-cell kinase, and tec (Table III). Those off-target effects could explain some of the unique toxicities seen with ibrutinib. Second-generation BTK inhibitors were designed to have fewer off-target effects, with the goal of improving efficacy and reducing toxicity. To date, second-generation BTK inhibitors examined in patients with r/r MCL include acalabrutinib, zanubrutinib, and tirabrutinib. As reported in clinical trials, those newer BTK inhibitors might have lower rates of the toxicities typically associated with ibrutinib such as bleeding, atrial fibrillation, and hypertension. Moreover, rates of common toxicities such as diarrhea, fatigue, and nausea might also be reduced (Table III).

**Acalabrutinib**

Acalabrutinib (ACP-196) is a novel, potent, orally bioavailable BTK inhibitor that was specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors such as ibrutinib. Acalabrutinib also binds Cys481 in the BTK active site, inactivating the enzyme and resulting in the inhibition of proliferation and survival signals in malignant B cells. However, acalabrutinib is more highly selective than ibrutinib, resulting in less off-target activity. It is therefore predicted to have fewer adverse effects, with virtually no inhibition of epidermal growth factor receptor, interleukin 2–inducible T-cell kinase, and tec (Table III, Figure 1). Indeed, acalabrutinib does not share the off-target antiplatelet activity of ibrutinib. In addition to its selectivity, the twice-daily dosing of acalabrutinib results in complete and continuous inhibition of BTK signalling over time, without increased toxic effects from inhibition of other kinases.

The efficacy and safety of acalabrutinib was evaluated in the single-arm phase II ACE-LLY-004 study, which included 124 subjects with r/r MCL enrolled between 12 March 2015 and 5 January 2016. Patients included in the study had relapsed after, or been refractory to, 1 or more but not more than 5 prior treatment regimens, with a median of 2 prior therapies. Participants received acalabrutinib 100 mg twice daily, continuously until progression or unacceptable drug-related toxicity. The primary endpoint was investigator-assessed ORR, based on the Lugano classification for NHL. Preliminary analysis of the data was performed after a median follow-up of 15.4 months. An ORR of 80.6% and a CR rate of 39.5% were reported based on investigator assessment.
Median dOR and pFS have not been reached; the estimated dOR and pFS rates at 12 months were 72.1% and 63.6% respectively.

The most common aEs (≥20% of patients; Table II, supplementary Appendix 1) were headache (38%), diarrhea (31%), fatigue (27%), and myalgia (21%). Headache events were mostly grade 1 (64%), and most patients (77%) experienced only 1 event. Headaches generally occurred early in treatment, at a median onset of 5 days, and were manageable, with a low rate of treatment withholding (4% of patients). The most frequently reported grades 3 and 4 aEs (≥5% of patients) were neutropenia (11%) and anemia (9%). Serious aEs reported in 2 or more patients included pneumonia (4.0%), anemia (3.2%), general physical health deterioration (2.4%), sepsis, tumour lysis syndrome, and vomiting (each 1.6%). No cases of atrial fibrillation occurred; 1 case of grade 3 hemorrhage was reported in a patient with a history of ulcer. Treatment discontinuations

### TABLE II  Adverse events reported with Bruton tyrosine kinase inhibitors

| Variable                  | Key trial, by inhibitor |
|---------------------------|-------------------------|
|                           | Ibrutinib Wang et al., 201529 (n=111) | Acalabrutinib Wang et al., 201814 (n=124) | Zanubrutinib Tam et al., 201738 (n=65) | Tirabrutinib Walter et al., 201649 (n=12) |
| Adverse events of interest (%) | Observed | Observed | Observed | All grades: not given |
| Bleeding                  | All grades: 50 | All grades: 31 | All grades: 25 | No increased risk |
|                           | Grade 3 or greater: 6 | Grade 3 or greater: 0.8 (1 case of grade 3 or greater GI hemorrhage with history of ulcer) | Grade 3 or greater: 3 | |
| Atrial fibrillation       | Observed | Not observed | Observed | Observed, but not drug-related |
|                           | Grade 3 or greater: 4.6 | All grades: 3 | All grades: 3 | |
| Common toxicities, all grades (%) |  |  |  |  |
| Diarrhea                  | 54 | 31 | 23 | 21 |
| Fatigue                   | 50 | 27 | 18 | Not given |
| Nausea                    | 33 | 18 | Not given | 15 |
| Headache                  | Not given | 38 | Not given | Not given |
| Hematologic toxicities, grade 3 or greater (%) |  |  |  |  |
| Neutropenia               | 17 | 10 | 9 | 10 |
| Thrombocytopenia          | 13 | 5 | 9 | 13 |
| Anemia                    | 11 | 12 | 11 | 13 |
| Infections, grade 3 or greater (%) |  |  |  |  |
| All reported              | 28 | 13 | URT: 2 | LRT: 5 |

*Adapted from Wu et al., 201612; Barf et al., 201711; Wang et al., 201529; Wang et al., 201814; Walter et al., 201649; and Tam et al., 201738. GI = gastrointestinal; URT = upper respiratory tract; LRT = lower respiratory tract.

### TABLE III  Molecular targets of the various Bruton tyrosine kinase (BTK) inhibitors

| Variable | Inhibitor |
|----------|-----------|
| Target   | Ibrutinib Acalabrutinib Zanubrutinib Tirabrutinib |
| BTK      | BTK BTK BTK BTK |
| Major off-targets | ITK EGFR TEC BMX |
| ITK      | Minimal (weak) |
| EGFR     | (weak) |
| TEC      | BTK |
| BMX      | |
| Anti-platelet activity | Yes No No No |

ITK = interleukin 2–inducible T cell kinase; EGFR = epidermal growth factor receptor; TEC = Tec protein tyrosine kinase; BMX = cytoplasmic tyrosine–protein kinase BMX.
Tirabrutinib is not yet approved in Canada or in any other country for the treatment of hematologic malignancies.

**Zanubrutinib**

Zanubrutinib is a second-generation BTK inhibitor that is also selective and irreversible\(^\text{18}\). In preclinical studies, less off-target activity was observed with zanubrutinib than with ibrutinib against a number of kinases, including interleukin 2-inducible T-cell kinase (Table \(\text{iii}\), supplementary Appendix 1)\(^\text{32}\). Both in the REC-1 MCL and TMD-8 xenograft models, zanubrutinib has induced dose-dependent antitumour effects that are superior to those seen with ibrutinib.

An open-label dose-escalation study examined the efficacy and safety of zanubrutinib in 99 patients with R/R NHL (supplementary Appendix 1)\(^\text{38}\). In patients with R/R MCL or diffuse large B-cell lymphoma \((n = 65)\), whose median age was 70 years and who had received 2 prior therapies, the ORR in the MCL subgroup was 88%, and the CR rate was 25% after a median follow-up of 9.5 months. The most common AEs (Table \(\text{iii}\), supplementary Appendix 1) included petechiae (25%), diarrhea (23%), and constipation (22%). The most frequently reported grades 3 and 4 AEs (≥5% of patients) were anemia (11%), thrombocytopenia (9%), neutropenia (9%), and pneumonia (6%). Severe hemorrhage and atrial fibrillation were each reported in 3% of patients. Zanubrutinib is not yet approved in Canada or in any other country for the treatment of hematologic malignancies.

**FUTURE DIRECTIONS**

Inhibitors of BTK have been examined for the treatment of a number of hematologic malignancies in addition to MCL, including CLL, Waldenström macroglobulinemia, diffuse large B-cell lymphoma, and marginal zone lymphoma (supplementary Appendix 2). Based on data from phase \(\text{ii}\)/\(\text{iii}\) studies, ibrutinib is now approved by Health Canada for patients with R/R MCL, for untreated patients with CLL and 17p deletion, for patients with CLL who have received at least 1 prior therapy, for patients with CLL who have received at least 1 prior therapy in combination with bendamustine and rituximab, for patients with marginal zone lymphoma who have received at least 1 prior anti-CD20–based therapy, for patients with Waldenström macroglobulinemia, and for patients with steroid-dependent or refractory chronic graft-versus-host disease\(^\text{49}\).

Ongoing phase \(\text{iii}\) trials comparing acalabrutinib and other novel BTK inhibitors with ibrutinib will aid in further clarifying the benefit of the second-generation BTK inhibitors (supplementary Appendix 2). Regimens that combine BTK inhibitors with other agents such as novel CD19 and CD20 antibodies, B-cell lymphoma 2 inhibitors, PI3K inhibitors, and ALK inhibitors will likely further improve outcomes. However, it will be important to consider the combined toxicity of those agents.

In CLL, a randomized trial of ibrutinib monotherapy compared with ibrutinib–rituximab did not demonstrate an improvement in PFS or OS with the addition of rituximab\(^\text{47}\). However, in vitro studies suggest that acalabrutinib does not result in off-target inhibition of T-cell or natural killer cell function\(^\text{18}\). Whether the addition of an anti-CD20 antibody to a BTK inhibitor will be beneficial will require further exploration.

\(\text{FIGURE 1} \)  Comparison of acalabrutinib and ibrutinib in competitive binding assays on wild-type and mutant kinases. Adapted with permission from Figure 3 in Barf et al., 2017\(^\text{31}\), which was published by ASPET under the CC BY-NC Attribution 4.0 International license.
monoclonal antibody to acalabrutinib results in additional benefit awaits the results of ongoing studies. Finally, it will be of interest to examine whether an alternative BTK inhibitor can overcome resistance to an initial BTK inhibitor, although such a result would not be expected for agents with the same binding site (for example, ibrutinib and acalabrutinib).

CANADIAN PERSPECTIVE

The availability of ibrutinib for the treatment of R/R MCL and other hematologic malignancies has clearly benefited patients by improving on the outcomes achieved with previously available agents. Despite the importance of ibrutinib for patients with R/R MCL, most patients do not achieve a CR, and some patients experience intolerable toxicities. Off-target effects such as bleeding, gastrointestinal toxicities, and atrial fibrillation are a concern for certain patients and can lead to discontinuation before progression of disease. Those toxicities can be difficult to manage and have emerged as a growing concern among hematologists as experience with ibrutinib in the management of CLL increases in clinical practice. The study by Mato et al. confirmed that, in a real-world setting, more patients discontinued ibrutinib because of toxicity than discontinued the drug in the clinical trials. Although those findings have not yet been demonstrated in MCL, the move to incorporate BTK inhibitors earlier in the treatment of MCL (with longer expected duration of response) suggests that discontinuation because of toxicity could also become a problem for patients with MCL. In addition, the greater dose of BTK inhibitors given in MCL compared with CLL might also result in greater toxicities for the patients with MCL. Patients who discontinue treatment (and possibly those who receive a reduced dose) are thus unable to obtain the maximal benefit of BTK inhibition. In addition, many patients might not be given ibrutinib because of comorbidities, including atrial fibrillation or conditions that increase the risk of bleeding.

Access to additional therapies that are effective and well-tolerated is a key unmet need for patients with R/R MCL, for whom few effective treatment options are available. The development of novel BTK inhibitors that aim to improve on the safety profile of ibrutinib by reducing off-target effects might produce therapies that are better tolerated. Early evidence suggests that second-generation BTK inhibitors are highly effective and might provide viable treatment options for patients with R/R MCL. With respect to those novel agents, the greatest amount of available data relates to acalabrutinib, which might have a toxicity profile better than that for ibrutinib, although comparative trials are lacking. It is unclear, however, whether the requirement for twice-daily dosing will hinder compliance. Nevertheless, the favourable toxicity profile seen in early trials of second-generation BTK inhibitors is encouraging, but must be confirmed with greater follow-up. Results of phase III trials in CLL comparing first-generation with second-generation BTK inhibitors will also aid in evaluating the comparative efficacy and safety of those agents. Additionally, data from patients treated with a second-generation BTK inhibitor after experiencing ibrutinib-related toxicities should clarify whether such patients could benefit from a more selective BTK inhibitor. Moreover, in light of attempts to combine BTK inhibitors with additional therapies in MCL patients, the use of BTK inhibitors with better toxicity profiles might improve the tolerability and efficacy of such combinations. In the meantime, additional effective and well-tolerated treatment options would allow physicians to consider the safety profile of available agents, patient comorbidities, and patient preference to select what could ultimately be the best treatment for their patients.

CONCLUSIONS

Mantle cell lymphoma is an aggressive disease with especially poor outcomes in the relapsed setting. Despite improved outcomes with ibrutinib, BTK inhibition is not curative in MCL, and additional treatments are needed. Real-world experience with ibrutinib demonstrates that the drug can be associated with toxicities that lead to treatment discontinuation or dose reduction for some patients. Second-generation BTK inhibitors were designed to improve on the efficacy and toxicity profiles of ibrutinib. Data from phase III trials indicate that the novel BTK inhibitors are highly effective. Moreover, they have demonstrated favourable toxicity profiles and might be associated with fewer troublesome AEs (including atrial fibrillation and major bleeding) than are seen with ibrutinib. Of the second-generation BTK inhibitors, acalabrutinib is the furthest into development and has been approved by the FDA in the relapsed setting. In the future, second-generation BTK inhibitors could also form a critical component of combination regimens, whose overall toxicity profile is of key importance. Longer follow-up, real-world experience, and comparative trials should aid in establishing their role. Notwithstanding the differences between ibrutinib and second-generation BTK inhibitors, the class effect seems clear in terms of efficacy in R/R MCL, and the introduction of competition in this market should be valuable for reducing the cost of those agents.

ACKNOWLEDGMENTS

The authors acknowledge financial and editorial support from AstraZeneca Canada Inc. for the development of this article. Medical writing assistance was provided by Anna Christofides of Impact Medicom Inc.

CONFLICT OF INTEREST DISCLOSURES

We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: CO has received honoraria from AstraZeneca, Janssen, AbbVie, Gilead, Lundbeck (Teva), Merck, and Hoffmann–La Roche Canada; NLBL has received honoraria from AstraZeneca, Gilead, Hoffmann–La Roche Canada, Laboratoires Servier, Seattle Genetics, Merck, Amgen, and Celgene; AC has received funding from AstraZeneca for the development of this article; LHS has received honoraria from Hoffmann–La Roche/Genentech, AbbVie, AstraZeneca, Celgene, TG Therapeutics, Amgen, Janssen, Lundbeck, and Seattle Genetics.

AUTHOR AFFILIATIONS

*Division of Hematology and Hematological Malignancies, University of Calgary and Foothills Medical Centre, Calgary, AB; ‘Department of Medicine, University of Toronto and Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON;
REFERENCES

1. Wang ML, Rule S, Martin P, et al. Targeting btk with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–16.

2. Janssen Inc. Imbruvica (Ibrutinib) Approved with Conditions for Relapsed or Refractory Mantle Cell Lymphoma Patients [online news release]. Toronto, ON: Janssen; 2015. [Available at: http://www.jansseninc.com/news/health-canada-approves-ibrutinib-mantle-cell-lymphoma; cited 12 July 2017]

3. Lymphoma Canada. Health Canada approves ibrutinib for mantle cell lymphoma [Web page]. Mississauga, ON: Lymphoma Canada; 2015. [Available online at: http://www.lymphoma.ca/research/health-canada-approves-ibrutinib-mantle-cell-lymphoma; cited 12 July 2017]

4. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–76.

5. Zhou Y, Wang H, Fang W, et al. Acalabrutinib in relapsed or refractory mantle-cell lymphoma-patients -52004821.html; cited 12 July 2017]

6. Canadian Cancer Society. Mantle cell lymphoma [Web page]. Toronto, ON: Canadian Cancer Society; n.d. [Available at: http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/mantle-cell-lymphoma/?region=on; cited 12 July 2017]

7. Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control 2012;19:227–35.

8. Alberta Health Services (ans). Clinical Practice Guideline: Lymphoma. Edmonton, AB: AHS; 2018. [Available online at: http://www.albertahealthservices.ca/assets/info/bc/cancer/if-hp-cancer-guide-lyhe002-lymphoma.pdf; cited 10 November 2018]

9. Hoster E, Dreyling M, Klapper W, et al. on behalf of the German Low Grade Lymphoma Study Group and the European Mantle Cell Lymphoma Network. A new prognostic index (mip) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–65. [Erratum in: Blood 2008;111:5761]

10. Hermine O, Hoster E, Walevski J, et al. on behalf of the European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (mcl younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016;388:565–75.

11. BC Cancer. Lymphoma [Web resource]. Vancouver, BC: BC Cancer; 2013. [Available at: http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-guidelines/lymphoma-chronic-leukemia-myeloma/lymphoma; cited 10 November 2018]

12. Advani RH, Buggy JJ, Sharmar JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88–94.

13. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016;387:770–8. [Erratum in: Lancet 2018;387:750]

14. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ace-ly-004): a single-arm, multicentre, phase 2 trial. Lancet 2018;391:659–67.

15. Mato AR, Lamanna N, Ujjani CS, et al. Toxicities and outcomes of ibrutinib-treated patients in the United States: large retrospective analysis of 621 real world patients. Blood 2016;128:3222.

16. Takada. FDA approves Velcade (bortezomib) for injection for previously untreated patients with mantle cell lymphoma [online news release]. Osaka, Japan: Takeda; 2014. [Available at: https://www.takeda.com/newsroom/newsreleases/2014/fda-approves-velcade-bortezomib-for-injection-for-previously-untreated-patients-with-mantle-cell-lymphoma; cited 10 November 2018]

17. Lymphoma Research Foundation. Mantle Cell Lymphoma: FDA Updates [Web resource]. New York, NY: Lymphoma Research Foundation; n.d. [Available at: https://www.lymphoma.org/aboutlymphoma/nhl/mcl/mclfdaupdates/; cited 27 June 2018]

18. European Medicines Agency (ema). Public Summary of Opinion on Orphan Designation: Temsirolimus for the Treatment of Mantle Cell Lymphoma. London, U.K.: ema; 2011. [Available online at: Public summary of opinion on orphan designation: Temsirolimus for the treatment of mantle cell lymphoma; cited 3 March 2019]

19. Actavis Inc. Act Bortezomib [product monograph]. Parsippany-Troy Hills, NJ: Actavis; 2016.

20. Janssen Inc. Imbruvica: Ibrutinib Capsules [product monograph]. Toronto, ON: Janssen; 2018.

21. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–74.

22. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105–12.

23. Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013;24:2892–7.

24. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide mono-therapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:4952–7.

25. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a U.K. phase II study suggest activity and possible gender differences. Br J Haematol 2012;159:154–63.

26. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II mcl-001 (emerge) study. J Clin Oncol 2013;31:3688–95.

27. Trneny M, Lamy T, Walevski J, et al. on behalf of the SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (mcl-002: SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol 2016;17:319–31.

28. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–9.

29. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of mcl patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739–45.

30. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma [blog post]. Bethesda, MD: NCI; 2017. [Available online at: https://www.cancer.gov/news-events/cancer-currents-blog/2017/acalabrutinib-fda-mantle-cell-lymphoma; cited 9 May 2018]
31. Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and \textit{in vivo} potency profile. \textit{J Pharmacol Exp Ther} 2017;363:240–52.

32. Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. \textit{J Hematol Oncol} 2016;9:80.

33. Byrd JC, Brown JR, O’Brien S, \textit{et al.} on behalf of the RESONATE investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. \textit{N Engl J Med} 2014;371:213–23.

34. Treon SP, Tripsas CK, Meid K, \textit{et al.} Ibrutinib in previously treated Waldenström’s macroglobulinemia. \textit{N Engl J Med} 2015;372:1430–40.

35. European Society for Medical Oncology (esmo). Ibrutinib, First FDA-approved therapy for marginal zone lymphoma [online news release]. Lugano, Switzerland: esmo; 2017. [Available at: http://www.esmo.org/Oncology-News/Ibrutinib-First-FDA-Approved-Therapy-for-Marginal-Zone-Lymphoma; cited 27 June 2018]

36. Inman S. FDA approves ibrutinib for mantle cell lymphoma [Web news article]. Cranbury, NJ: Intellisphere, LLC; 2013. [Available at: http://www.onclive.com/web-exclusives/fda-approves-breakthrough-ibrutinib-for-mcl; cited 10 November 2018]

37. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. \textit{Hematol Oncol Clin North Am} 2007;21:841–54.

38. Tam C, Grigg AP, Opat S, \textit{et al.} The \textit{btk} inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. \textit{Blood} 2015;126:832.

39. Walter HS, Rule SA, Dyer MJ, \textit{et al.} A phase 1 clinical trial of the selective \textit{btk} inhibitor oxo/\textit{gs}-4059 in relapsed and refractory mature B-cell malignancies. \textit{Blood} 2016;127:411–19.

40. Wang M, Goy A, Martin P, \textit{et al.} Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. \textit{Blood} 2014;124:4471.

41. Wang ML, Lee H, Chuang H, \textit{et al.} Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. \textit{Lancet Oncol} 2016;17:48–56.

42. Tam CS, Anderson MA, Pott C, \textit{et al.} Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. \textit{N Engl J Med} 2018;378:1211–23.

43. Byrd JC, Harrington B, O’Brien S, \textit{et al.} Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. \textit{N Engl J Med} 2016;374:323–32.

44. Patel V, Balakrishnan K, Bibikova E, \textit{et al.} Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. \textit{Clin Cancer Res} 2017;23:3734–43.

45. Bye AP, Unsworth AJ, Desborough MJ, \textit{et al.} Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. \textit{Blood Adv} 2017;1:2610–23. [Erratum in: \textit{Blood Adv} 2018;2:3515]

46. Wu J, Zhang M, Liu D. Bruton tyrosine kinase inhibitor oxo/\textit{gs}-4059: from bench to bedside. \textit{Oncotarget} 2017;8:7201–7.

47. Burger JA, Sivina M, Ferrajoli A, \textit{et al.} Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL). \textit{Blood} 2017;130(suppl 1):427.

48. Fowler NH, Coleman M, Stevens DA, \textit{et al.} Acalabrutinib alone or in combination with rituximab (\textit{a}) in follicular lymphoma (FL) [abstract 7549]. \textit{J Clin Oncol} 2018;36:. [Available online at: \textit{http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.7549; cited 18 January 2019]